Search Hotels in Mill Valley

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Breaking Down Exelixis: 7 Analysts Share Their Views

January 30, 2024

Via Benzinga

January 25, 2024

Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024

January 23, 2024

Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation.

NASDAQ:EXEL is showing good growth, while it is not too expensive.

December 21, 2023

Via Chartmill

6 Analysts Have This to Say About Exelixis

December 13, 2023

Via Benzinga

Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study

January 23, 2024

Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.

Via Benzinga

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

January 22, 2024

From Bristol Myers Squibb

Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL.

10 Health Care Stocks Whale Activity In Today's Session

January 22, 2024

Via Benzinga

NASDAQ:EXEL, a growth stock which is not overvalued.

November 29, 2023

Via Chartmill

Looking for growth without the hefty price tag? Consider NASDAQ:EXEL.

November 06, 2023

EXELIXIS INC (NASDAQ:EXEL) is showing decent growth, but is still valued reasonably.

Via Chartmill

3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024

January 21, 2024

These top-rated biotech stocks are going to be in high demand in January and in every other month in 2024.

European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets

January 18, 2024

These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.

3 Pharma Stocks Could Be the Pills Your Portfolio Needs

January 18, 2024

Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review

January 12, 2024

The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.

Via Investor's Business Daily

Topics ETFs

Jim Cramer Likes This 'Well-Run' Airline, Says This Entertainment Stock Has 'Balance Sheet From Hell'

January 12, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Franco-Nevada Corporation (NYSE: FNV) is a "great diversified

Via Benzinga

Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.

January 11, 2024

Investors should take note ofEXELIXIS INC (NASDAQ:EXEL), a growth stock that remains attractively priced.

Via Chartmill

Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?

January 08, 2024

Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an

Via Benzinga

Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes

January 08, 2024

Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco.

Via Investor's Business Daily

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

January 07, 2024

Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024

January 02, 2024

Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023

December 07, 2023

Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

December 04, 2023

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

December 04, 2023

From Arcus Biosciences

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

November 29, 2023

Via FinancialNewsMedia

Topics Death

Exposures Death

Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023

November 21, 2023

Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

November 10, 2023

Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.

Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures

November 09, 2023

Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.

3 Biotech Stocks With the Strongest Clinical Pipelines

November 08, 2023

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

3 Promising Biotech Stocks Flying Under the Radar

November 08, 2023